Home LiteratureArticle Details
PMID: 25704079 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells.

International journal of cancer ·Vol. 137 ·No. 6 ·2015-09-15 ·Pages 1491-7

Anastasiadou E, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F, Frati L, Ferretti E, Faggioni A, Trivedi P

Abstract

The association of Epstein-Barr virus (EBV) with plasmacytoid malignancies is now well established but how the virus influences microRNA expression in such cells is not known. We have used multiple myeloma (MM) cell lines to address this issue and find that an oncomiR, miR-21 is induced after in vitro EBV infection. The PU.1 binding site in miR-21 promoter was essential for its activation by the virus. In accordance with its noted oncogenic functions, miR-21 induction in EBV infected MM cells caused downregulation of p21 and an increase in cyclin D3 expression. EBV infected MM cells were highly tumorigenic in SCID mice. Given the importance of miR-21 in plasmacytoid malignancies, our findings that EBV could further exacerbate the disease by inducing miR-21 has interesting implications both in terms of diagnosis and future miR based therapeutical approaches for the virus associated plasmacytoid tumors.

Keywords
EBV miR-21 multiple myeloma plasma cells
MeSH Terms
Animals B-Lymphocytes/metabolism Binding Sites/genetics Cell Differentiation/genetics Cyclin D3/genetics Cyclin-Dependent Kinase Inhibitor p21/genetics Down-Regulation/genetics Epstein-Barr Virus Infections/complications,genetics Herpesvirus 4, Human Mice Mice, SCID MicroRNAs/genetics Multiple Myeloma/genetics,virology Promoter Regions, Genetic
Chemicals
Cyclin D3 Cyclin-Dependent Kinase Inhibitor p21 MIRN21 microRNA, mouse MicroRNAs
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Anastasiadou Eleni
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
Garg Neha
Department of Molecular Medicine, La Sapienza University, Rome, Italy.
Bigi Rachele
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
Yadav Shivangi
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
Campese Antonio Francesco
Department of Molecular Medicine, La Sapienza University, Rome, Italy.
Lapenta Caterina
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy.
Spada Massimo
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy.
Cuomo Laura
Department of Clinical Pathology, San Filippo Neri Hospital, Rome, Italy.
Botta Annalisa
Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
Belardelli Filippo
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy.
Frati Luigi
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
Ferretti Elisabetta
Department of Molecular Medicine, La Sapienza University, Rome, Italy.
Faggioni Alberto
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
Trivedi Pankaj
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
1097-0215
Published
2015-09-15
Epub
2015-00-04
Pages
1491-7
Language
English
Region
United States
NLM ID
0042124
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com